Archive · 7 Jun 2025
Dr. Reddy's Navigates Revenue Shifts with Strategic Investments
Imagine Dr. Reddy's makes medicine.
For a few years, a certain medicine (gRevlimid) made them a lot of money.
But that money is starting to dry up.
Now, they are investing in new things, like a drug for diabetes (GLP-1RA).
They are also buying other companies and teaming up with Nestle.
The company also makes medicines that help people stop smoking.
While they are working on new ways to make money, there might be a little dip in how much money they make for a bit.
They are also spending a lot of money to make even more new medicines.
Dr. Reddy's experienced significant gains from gRevlimid sales in the US, ending by FY26.
The company invested heavily to offset revenue gaps as gRevlimid sales decline.
Dr. Reddy's is focusing on GLP-1RA generics, with potential in Canada starting January 2026.
Acquired Nicotine Replacement Therapy products from Haleon and has a JV with Nestle.
The company maintains high R&D investments, including biosimilars and early-stage oncology assets.
- Who
- Dr. Reddy’s Laboratories
- What
- Dr. Reddy’s is facing changes in revenue and investment strategies.
- When
- FY22-25 and January 2026
- Where
- United States, Canada, India, Brazil, Europe, and other global markets
- Why
- Due to the nearing end of gRevlimid sales and strategic investments.
Potential Challenges
Positive Outlook
Revenue Growth
Potential Challenges
The loss of gRevlimid sales will lead to revenue slowdown.
Positive Outlook
Long-term drivers and investments could generate strong growth.
Investment Impact
Potential Challenges
The scope of value from new investments is yet to be fully ascertained.
Positive Outlook
Upside potential exists from new investments.
- FY22-25 Revenue Growth
- 15% CAGR
- FY22-25 PAT Growth
- 36% CAGR
- gRevlimid Sales Growth (FY22-25)
- 24% CAGR
- Net Cash (March 2025)
- ₹2,454 crore
- EBITDA Margin Expansion
- 400 bps (FY19-22 average of 22.6% to 26.6% in FY22-25)
- NRT Acquisition Consideration
- £500 million